Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. 더 보기
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – –...
REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1312 | -8.86486486486 | 1.48 | 1.48 | 1.2733 | 1783342 | 1.3447846 | CS |
4 | -0.1212 | -8.24489795918 | 1.47 | 1.7699 | 1.2733 | 1817443 | 1.4722573 | CS |
12 | 0.592 | 78.2241014799 | 0.7568 | 2.43 | 0.6655 | 5267883 | 1.45286578 | CS |
26 | -0.3112 | -18.7469879518 | 1.66 | 2.43 | 0.6655 | 3520198 | 1.34255893 | CS |
52 | -1.2512 | -48.1230769231 | 2.6 | 2.87 | 0.6655 | 2898620 | 1.65949598 | CS |
156 | -11.0712 | -89.1400966184 | 12.42 | 14.11 | 0.6655 | 2520171 | 3.75847009 | CS |
260 | -17.5212 | -92.8521462639 | 18.87 | 23.03 | 0.6655 | 1909900 | 6.59542238 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관